FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Epithalon

Epitalon / Epithalone / AEDG peptide

Longevity & Anti-Aging

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland, developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Its primary mechanism of action is activation of the enzyme telomerase, which elongates telomeres at the ends of chromosomes, theoretically addressing one of the fundamental mechanisms of cellular aging. It is one of the most researched anti-aging peptides, with over 30 years of study primarily from Russian academic institutions.

작용 메커니즘

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase by inducing the catalytic subunit hTERT. Telomerase elongates telomeres, the protective chromosomal endcaps that shorten with each cell division. May slow cellular aging and extend replicative lifespan.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 5-10mg daily via subcutaneous injection for 10-20 day cycles, repeated every 4-6 months. Khavinson protocol: 10mg daily x 10 days, twice yearly.

연구 노트

Clinical Research Status

Epithalon has been studied in multiple clinical settings in Russia, with published data on elderly patients showing improvements in melatonin production, immune function, and cardiovascular parameters. Khavinson's research group published studies spanning over 15 years of follow-up in geriatric cohorts receiving epithalamin/epithalon. However, these studies largely lack the rigorous double-blind placebo-controlled design expected by Western regulatory agencies, and no FDA IND application has been filed.

Key Published Findings

In vitro studies demonstrate that Epithalon activates telomerase in human somatic cells, increasing telomere length and extending cell replicative capacity beyond the Hayflick limit. Animal studies in rodents showed extension of maximum lifespan by 13-25% and reduction in spontaneous tumor incidence. Published human data from Khavinson's group report restoration of melatonin cycling, improved immune markers (T-cell function, thymus recovery), and reduced cardiovascular mortality in elderly patients followed for 6-12 years.

Safety Profile

No significant adverse effects have been reported in published clinical studies spanning decades of use in Russian geriatric populations. The tetrapeptide's small size (4 amino acids) and identity with an endogenous pineal product suggest low immunogenicity and toxicity risk. Animal studies at doses far exceeding therapeutic ranges showed no mutagenic, teratogenic, or carcinogenic effects. The activation of telomerase raises theoretical oncological concerns, though published data paradoxically show reduced tumor incidence.

Drug Interactions & Contraindications

No documented drug interactions exist in published literature. Theoretical concern exists regarding concurrent use with immunosuppressive therapy, as Epithalon may stimulate immune function. The telomerase activation mechanism raises theoretical questions about use in patients with active or recently treated cancers, though available evidence does not support increased cancer risk. Melatonin-modulating effects suggest caution with exogenous melatonin or medications affecting circadian rhythm.

Comparison to Related Compounds

Epithalon is distinguished from other anti-aging peptides (GHK-Cu, BPC-157) by its specific telomerase activation mechanism rather than growth factor or wound healing pathways. Unlike TA-65 (a telomerase activator derived from astragalus), Epithalon is a direct peptide bioregulator rather than a plant extract. Khavinson's broader research program identified tissue-specific bioregulatory peptides for multiple organs (Thymalin for thymus, Cortexin for brain), with Epithalon targeting the pineal-aging axis specifically.

Community Observations

Most commonly administered as 5-10mg subcutaneously daily for 10-20 day cycles, repeated every 4-6 months, following the protocol described in Khavinson's published research. Injectable administration is preferred due to the peptide's small size and potential for GI degradation with oral dosing. Users frequently combine it with other longevity-focused interventions and report improvements in sleep quality, energy levels, and general well-being, though objective telomere measurements are rarely obtained due to cost.

반감기

~30 minutes

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 24 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

EpitalonEpithaloneAEDG peptide

자주 묻는 질문

Epithalon란 무엇인가요?

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland, developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Its primary mechanism of action is activation of the enzyme telomerase, which elongates telomeres at the ends of chromosomes, theoretically addressing one of the fundamental mechanisms of cellular aging. It is one of the most researched anti-aging peptides, with over 30 years of study primarily from Russian academic institutions.

Epithalon는 어떻게 작용하나요?

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase by inducing the catalytic subunit hTERT. Telomerase elongates telomeres, the protective chromosomal endcaps that shorten with each cell division. May slow cellular aging and extend replicative lifespan.

Epithalon의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

Epithalon의 반감기는 얼마인가요?

~30 minutes

Epithalon의 다른 이름은 무엇인가요?

Epitalon, Epithalone, AEDG peptide

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기